DECRYPTION – Life expectancy is improving thanks to new therapies.
The paradigm shift is radical. From an extremely bleak prognosis just a few years ago, lung cancer has moved into an in-between situation, opening the door to many possibilities. “A patient with metastasized lung cancer is no longer told: ‘We can’t cure you'”illustrates the Pr Benjamin Besse, director of clinical research at Gustave-Roussy. “Terms “chronic disease” or “disease control” seems more appropriate to me, because some treatments can work very well, and for a long time.”
Admittedly, lung cancer is both one of the most common in France (46,000 new cases per year in 2018 according to the Inca), and the most deadly in men, the second in women (30,000 deaths in overall in 2018). “But between the two, there are people who live with the disease”, recalls Laure Guéroult Accolas, founder of Patients in Network. “Some patients with stage 4 cancer (the most serious, Editor’s note) can, through immunotherapy…
This article is for subscribers only. You have 80% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
Already subscribed? Login